INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 279 filers reported holding INTELLIA THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.98 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,534,248 | -17.6% | 80,147 | +6.3% | 0.00% | 0.0% |
| Q2 2023 | $3,074,608 | +11.3% | 75,395 | +1.7% | 0.00% | 0.0% |
| Q1 2023 | $2,762,303 | +9.3% | 74,116 | +2.3% | 0.00% | 0.0% |
| Q4 2022 | $2,526,630 | -34.1% | 72,417 | +5.7% | 0.00% | 0.0% |
| Q3 2022 | $3,834,000 | +2.1% | 68,524 | -5.6% | 0.00% | 0.0% |
| Q2 2022 | $3,756,000 | -23.4% | 72,556 | +7.6% | 0.00% | 0.0% |
| Q1 2022 | $4,902,000 | -36.2% | 67,451 | +3.9% | 0.00% | -50.0% |
| Q4 2021 | $7,680,000 | +0.4% | 64,948 | +13.9% | 0.00% | 0.0% |
| Q3 2021 | $7,649,000 | +11.3% | 57,018 | +34.3% | 0.00% | 0.0% |
| Q2 2021 | $6,873,000 | +128.6% | 42,449 | +13.4% | 0.00% | +100.0% |
| Q1 2021 | $3,006,000 | -15.5% | 37,447 | -42.8% | 0.00% | 0.0% |
| Q4 2020 | $3,558,000 | +91.3% | 65,416 | -30.1% | 0.00% | 0.0% |
| Q3 2020 | $1,860,000 | +51.2% | 93,549 | +59.8% | 0.00% | 0.0% |
| Q2 2020 | $1,230,000 | +330.1% | 58,529 | +184.8% | 0.00% | – |
| Q1 2020 | $286,000 | +70.2% | 20,554 | +79.1% | 0.00% | – |
| Q4 2019 | $168,000 | +28.2% | 11,476 | +13.1% | 0.00% | – |
| Q3 2019 | $131,000 | +8.3% | 10,150 | +28.4% | 0.00% | – |
| Q2 2019 | $121,000 | +21.0% | 7,907 | +34.8% | 0.00% | – |
| Q1 2019 | $100,000 | +25.0% | 5,864 | 0.0% | 0.00% | – |
| Q4 2018 | $80,000 | -48.7% | 5,864 | +8.1% | 0.00% | – |
| Q3 2018 | $156,000 | +4.7% | 5,427 | 0.0% | 0.00% | – |
| Q2 2018 | $149,000 | +129.2% | 5,427 | +75.4% | 0.00% | – |
| Q1 2018 | $65,000 | -25.3% | 3,094 | -30.9% | 0.00% | – |
| Q4 2017 | $87,000 | -16.3% | 4,479 | +5.9% | 0.00% | – |
| Q3 2017 | $104,000 | +79.3% | 4,231 | +16.5% | 0.00% | – |
| Q2 2017 | $58,000 | +75.8% | 3,632 | +51.9% | 0.00% | – |
| Q1 2017 | $33,000 | +13.8% | 2,391 | +8.6% | 0.00% | – |
| Q4 2016 | $29,000 | +11.5% | 2,201 | +41.0% | 0.00% | – |
| Q3 2016 | $26,000 | -25.7% | 1,561 | 0.0% | 0.00% | – |
| Q2 2016 | $35,000 | – | 1,561 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
| MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
| Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
| Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
| Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
| ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
| Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
| Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
| TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |